Clinical Trial

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial

Study acronym: OCEAN(a)-CCTA
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this trial is to evaluate the effect of olpasiran, compared to placebo, on non-calcified plaque (NCP) volume as measured by Coronary Computed Tomography Angiography (CCTA).
Trial Details
NCT Number NCT07293260
Lead Sponsor Amgen
Conditions Cardiovascular Disease
Enrollment 406 participants
Start Date 2026-03-23
Primary Completion 2028-06-15 (estimated)
Study Completion 2028-06-15 (estimated)
Updated on ClinicalTrials.gov 2026-04-16